On January 8, 2024, Revance Therapeutics, Inc. announced that Mr. Dustin Sjuts is stepping down from his current position as President of the Company, effective as of March 31, 2024. Further, in connection with the announced departure of Dustin Sjuts, President of Revance, effective March 31, 2024, Mark Foley, Chief Executive Officer, will reassume responsibility for the company?s therapeutics business along with clinical, regulatory, quality, R&D and medical. Reporting to Mark across these functions is David Hollander, MD, MBA, Chief Medical Officer, who will take on the additional role of Global Therapeutics Franchise Lead.

In this role, David will lead the company's global therapeutics strategy as well as U.S. commercial sales, marketing and payor functions. Tobin Schilke, Chief Financial Officer, will assume responsibility over the company?s manufacturing and supply chain operations.